Introduction {#s1}
============

Prostate is the most common male sex-specific cancer ([@bib11]). Prostate cancer progression is controlled by androgen steroid hormones including testosterone and its active metabolite 5-α dihydroxytestosterone. Androgens stimulate androgen receptor (AR) signalling in prostate cancer cells to control transcription, including of genes that regulate the cell cycle, central metabolism and biosynthesis, as well as housekeeping functions ([@bib40]). The roles of both androgens and the AR in transcription have been intensively investigated. However, androgens and the AR also regulate alternative pre-mRNA splicing through still largely unknown mechanisms ([@bib50]; [@bib58]). This represents a very important knowledge gap: alternative splicing patterns in cancer cells can generate protein isoforms with different biological functions ([@bib52]), and is a key process in the generation of biological heterogeneity in prostate cancer ([@bib57]).

Androgens are also closely linked to prostate cancer treatment, with androgen deprivation therapy (ADT) being the principal pharmacological strategy for locally advanced and metastatic disease. ADT utilises drugs to inhibit gonadal and extra-gonadal androgen biosynthesis and competitive AR antagonists to block androgen binding and abrogate AR function ([@bib40]). ADT delays disease progression, but after 2--3 years tumours often grow again, developing castration resistance with a median survival time of 16 months ([@bib33]). The central role of androgens and the AR in prostate cancer, and the poor clinical outlook of castration-resistance prostate cancer (CRPCa), have made it crucially important to identify androgen-regulated target genes and mechanisms of function --particularly those that relate to metastasis. The process of epithelial-mesenchymal transition (EMT) plays a pivotal role in prostate cancer metastasis ([@bib24]; [@bib43]; [@bib44]; [@bib62]; [@bib81]). While the mechanisms driving EMT in prostate cancer are poorly understood, ADT has recently been shown to directly induce EMT in both mouse and human prostate tissue ([@bib64]; [@bib83]). Importantly, changes in alternative splicing patterns can have dramatic effects on EMT and on metastatic disease progression ([@bib55]).

While the mechanisms through which androgens regulate splicing control are not well understood, splicing itself takes place in the spliceosome, which is a multi-component structure containing a core of essential proteins and small nuclear RNAs ([@bib53]). Splicing inclusion of alternative exons is often controlled by splicing regulator proteins that bind either to regulated exons or within their adjacent flanking intron sequences ([@bib19]). The estrogen and progesterone steroid nuclear hormone receptors control splicing via recruitment of alternative splicing regulators (including the RNA helicases Ddx5 and Ddx17) ([@bib7]; [@bib6]; [@bib5]), and by changing RNA polymerase II extension rates and chromatin structure to affect splice site selection ([@bib35]; [@bib51]). Steroid hormones can also drive selection of alternative promoters to include different upstream exons in mRNAs ([@bib17]; [@bib50]). However, to what extent the above mechanisms may contribute to androgen-mediated splicing is largely unknown.

We reasoned that a potential model to unify the role of androgens and the AR in transcription and splicing control could be via transcriptional regulation of genes that encode splicing regulatory proteins.To address this we analysed a recently described set of genes that reciprocally change expression in response to androgen stimulation in culture and ADT in patients ([@bib49]). Here we identify AR-mediated transcriptional control of the key splicing regulator protein Epithelial Splicing Regulator Protein 2 (ESRP2). Importantly, many ESRP2-regulated exons switch splicing in response to androgen stimulation. ESRP2 and its close relative ESRP1 (60% identical to ESRP2 protein) are important regulators of epithelial alternative splicing patterns ([@bib8]; [@bib32]; [@bib52]; [@bib70]; [@bib79]; [@bib77]; [@bib78]), reduced expression of which can drive critical aspects of EMT ([@bib26]; [@bib55]; [@bib79]). Our data identify an AR-ESRP2 axis controlling splicing patterns in prostate cancer cells, and further suggest that reduced ESRP2 levels in response to ADT may inadvertently help prime prostate cancer cells to facilitate longer term disease progression.

Results {#s2}
=======

*ESRP2* is a direct target for AR regulation in prostate cancer cells {#s2-1}
---------------------------------------------------------------------

To first gain insight into how androgens may mediate patterns of splicing control, we analysed a recently generated dataset of genes that exhibit reciprocal expression patterns on acute androgen stimulation in vitro versus clinical ADT ([@bib49]). While a number of genes encoding splicing factors changed expression in response to acute androgen stimulation in vitro, *ESRP2* also showed a reciprocal expression switch between acute androgen stimulation in culture and ADT in patients ([@bib49]). *ESRP2* expression decreased following ADT in 7/7 prostate cancer patients ([@bib59]) ([Figure 1A](#fig1){ref-type="fig"}). Furthermore, RNAseq data prepared from different stages of LTL331 patient-derived xenografts ([@bib2]) showed reduced *ESRP2* mRNA levels following castration and relapse neuroendocrine prostate cancer (NEPC, [Figure 1B](#fig1){ref-type="fig"}). We similarly analysed expression of *ESRP1. ESRP1* is a close paralog of *ESRP2*, but was not identified in our initial screen to identify androgen-regulated genes ([@bib49]). *ESRP1* expression levels also reduced following ADT ([Figure 1A](#fig1){ref-type="fig"}). However, *ESRP1* showed less change in gene expression compared to *ESRP2* in patient-derived xenografts following castration or relapse NEPC ([Figure 1C](#fig1){ref-type="fig"}) ([@bib2]).

![*ESRP2* is a direct target for AR regulation in prostate cancer cells.\
(**A**) Analysis of RNAseq data from human prostate cancer pre- and post- androgen deprivation therapy (ADT) ([@bib12]; [@bib59]) shows that there is a significant downregulation of ESRP1 and *ESRP2* mRNA following ADT in all seven patients tested (p=6e-04, Mann Whitney U test). (**B--C**) RNAseq data from LTL331 patient-derived xenografts grown in mice ([@bib2]) show a greater reduction in (**B**) *ESRP2* mRNA levels following castration compared to (**C**) ESRP1 mRNA levels. (**D**) Western blot analysis of ESRP2 levels in a range of prostate cancer cell lines (actin was used as a loading control). (**E**) Western blot analysis of ESRP1 levels in prostate cancer cell lines. (**F**) Real-time PCR analysis of *ESRP2* and *ESRP1* mRNAs in LNCaP cells grown in steroid deplete (SD) or androgen (A+) treated conditions for 24 hr (statistical significance calculated by t test). (**G**) Real-time PCR analysis of ESRP2 mRNA in RWPE-1 cells grown in steroid deplete (SD) or androgen (A+) treated conditions for 24 hr. (**H**) Western blots analysis of ESRP1 and 2 protein in LNCaP cells treated with 10nm R1881 (androgens) for 24 and 48 hr. (**I**) Quantitative analysis (real-time PCR) of *ESRP2* mRNA expression over a 24 hr time course following androgen exposure. (**J**) Real-time PCR analysis of AR-ChIP performed in LNCaP cells treated with 10nM R1881 for 24 hr revealed AR binding proximal to the *ESRP2* gene. (**K**) Induction of *ESRP2* is evident in LNCaP cells treated with R1881 concentrations between 1 to 100 nM (p value of 0.029 is for the comparison between 0 nm and 10nm R1881). Statistical significances were calculated by t tests, apart from (**A**) which used a Mann Whitney U test, and H which used Two-way ANOVA. Real time PCR analyses used at least three independent biological replicates (RNA prepared from separate samples), apart from the AR ChIP (panel I) for which each value shown is a mean of 3 technical replicates.](elife-47678-fig1){#fig1}

Further analyses supported androgen-mediated control of *ESRP2* but not *ESRP1* in prostate cancer cell lines. Western blots detected high endogenous levels of both ESRP1 and ESRP2 proteins within the AR positive LNCaP and CWR22 RV1 prostate cancer cell lines, as compared to the AR negative PC3 and DU145 prostate cancer cell lines ([Figure 1D and E](#fig1){ref-type="fig"}). However, qPCR analysis showed that while androgens activated *ESRP2* gene expression in response to in AR-positive LNCaP cells, this was not observed for *ESRP1* gene expression ([Figure 1F](#fig1){ref-type="fig"}). Androgen mediated-control of *ESRP2* expression was also detected in two additional AR-expressing prostate cell lines (VCaP and RWPE-1, [Figure 1G](#fig1){ref-type="fig"}). ESRP2 protein expression was detected 48 hr after androgen exposure, with ESRP1 protein levels not changing over this same time-period ([Figure 1H](#fig1){ref-type="fig"}). The specificity of the ESRP1 and ESRP2 antibodies used in these experiments was confirmed by detection of over-expressed protein and detection of siRNA mediated protein depletion by western blot ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

Further experimental analyses also supported *ESRP2* as an early and so likely direct target for transcriptional control by the AR: (i) *ESRP2* gene expression in LNCaP cells was rapidly induced in response to 10 nM of the synthetic androgen analogue R1881 (methytrienolone) ([Figure 1I](#fig1){ref-type="fig"}). (ii) Chromatin immunoprecipitation (ChIP) from LNCaP cells confirmed direct AR binding to a site within 20 Kb of the *ESRP2* gene promoter that had been previously predicted from a genome-wide study (at position chr16: 68210834--68211293 on human genome assembly hg38) ([@bib42]) ([Figure 1J](#fig1){ref-type="fig"}). The AR ChIP signal adjacent to *ESRP2* was similar to that detected in parallel for *KLK3* (encoding prostate specific antigen, or PSA), which is a known AR-regulated gene. (iii) Consistent with *ESRP2* regulation at physiological androgen concentrations, *ESRP2* transcription in LNCaP cells was induced over a wide range of R1881 concentrations, ranging from 1 nM to 100 nM ([Figure 1K](#fig1){ref-type="fig"}). Each of these above data are consistent with AR-mediated regulation of *ESRP2* expression levels within prostate cancer cell lines as well as tissue.

*ESRP2* and its paralog *ESRP1* are highly expressed in primary prostate tumours and inhibit tumour growth in vivo {#s2-2}
------------------------------------------------------------------------------------------------------------------

We next monitored *ESRP1* and *ESRP2* expression profiles from prostate cancer patients. Meta-analysis of 719 clinical prostate cancer tumours from 11 previously published studies detected significant up-regulation of both *ESRP1* and *ESRP2* in 9/11 datasets ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}) ([@bib3]; [@bib10]; [@bib18]; [@bib23]; [@bib36]; [@bib38]; [@bib41]; [@bib65]; [@bib66]; [@bib72]; [@bib73]; [@bib75]). We experimentally validated this meta-analysis using two independent panels of clinical samples. Real-time PCR showed significant up-regulation of both *ESRP1* and *ESRP2* mRNA in (1) prostate carcinoma relative to benign prostate hyperplasia (BPH) ([Figure 2A](#fig2){ref-type="fig"}); and (2) in nine prostate tumour samples relative to matched normal tissue from the same patient ([Figure 2B](#fig2){ref-type="fig"}). A recent study by [@bib74] identified a molecular subgroup of prostate cancers with metastatic potential at presentation. Within this dataset *ESRP1* was 2.76 fold up-regulated in the 'metastatic-subgroup' compared to the 'non-metastatic subgroup'. Using RNA from a subset of samples from the Walker et al. study, we confirmed significant (p\<0.05) upregulation of the *ESRP1* gene in primary prostate cancer patients presenting with a metastatic biology ([Figure 2C](#fig2){ref-type="fig"}). *ESRP2* gene expression did not significantly increase in the 20 samples studied. We also used these same samples to assess if the observed up-regulation of *ESRP1* and *ESRP2* could result from prostate tumours consisting of a more pure population of epithelial-derived cells compared to matched tissue. Arguing against this possibility, levels of E-Cadherin were not significantly increased between BPH compared to prostate carcinoma, or between matched tumour and normal prostate tissue from patients ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![ESRP2 and its paralog ESRP1 are highly expressed in primary prostate tumours.\
(**A**) Real-time PCR analysis of *ESRP1* and *ESRP2* mRNA from patients with benign prostate hyperplasia (BPH) and 17 malignant samples from transurothelial resection of the prostate (TURP) samples. (**B**) Real-time PCR analysis of *ESRP1* and *ESRP2* mRNA from normal and matched prostate cancer tissue from nine patients obtained from radical prostatectomy. (**C**) Analysis of *ESRP1* and *ESRP2* mRNA levels in samples from the [@bib74] cohort. Statistical analysis in parts (**A**)-(**C**) were performed using t tests. (**D**) Interrogation of the TCGA PRAD (PRostate ADenocarcinoma) cohort using KM-express ([@bib12]). *ESRP1* expression levels linked to a reduced time to PSA biochemical recurrence (bifurcate gene expression at average, log-rank test p=0.022). Over-expression of (**E**) ESRP1, (**F**) ESRP2, or (**G**) both ESRP1 and ESRP2 in PC3 cells significantly slowed the growth of prostate cancer xenografts in vivo. Data were analysed by Two-way ANOVA, and the p value is for the overall difference between two groups.\
10.7554/eLife.47678.008Figure 2---source data 1.Meta-analysis of 719 clinical prostate cancer tumours from 11 previously published studies detected significant up-regulation of both *ESRP1* and *ESRP2* in 9/11 datasets.](elife-47678-fig2){#fig2}

Each of the above data showed that *ESRP1* and *ESRP2* expression levels are relatively high in primary prostate cancer compared to normal prostate tissue. High *ESRP2* expression was not prognostic of disease progression in the TCGA (PRostate ADenocarcinoma) PRAD cohort analysed using KM-express ([@bib12]), but high expression of *ESRP1* associated with a significantly reduced time to first biochemical recurrence (p=0.022) ([Figure 2D](#fig2){ref-type="fig"}). We tested our antibodies against ESRP1 and ESRP2 proteins on prostate cancer FFPE tissue and cell blocks, but they did not pass our stringent quality control tests ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). While this manuscript was in preparation, another group used an alternative ESRP1 antibody to show up-regulation of ESRP1 in 12,000 prostate cancer tissue microarray tumours ([@bib21]).

We next investigated the effects of ESRP1/2 expression on the biology of prostate cancer cells in vivo. Because of their low normal endogenous expression profiles ([Figure 1C and D](#fig1){ref-type="fig"}), we selected PC3 and DU145 cells to study the effects on prostate cancer cells of ESRP1/ESRP2 protein up-regulation. Ectopic expression of ESRP1 and ESRP2 protein expression in AR negative PC3 and DU145 cell line models reduced prostate cancer cell growth in vitro ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Over-expression of both ESRP1 and ESRP2 (either alone or together) in PC3 cells also significantly slowed growth of prostate cancer xenografts in vivo ([Figure 2E--G](#fig2){ref-type="fig"}). Taken together, the above data show that ectopic expression of ESRP1 and ESRP2 proteins slow the growth of PC3 and DU145 prostate cancer cell lines and are strongly suggestive that high levels of ESRP2 protein inhibit growth of prostate cancer cells.

Identification of endogenous ESRP1/ESRP2-regulated targets in prostate cancer cells {#s2-3}
-----------------------------------------------------------------------------------

To enable us to test whether androgens may control splicing indirectly via transcriptional regulation of *ESRP2*, we next set out to identify a panel of endogenous ESRP2-responsive exons within prostate cancer cells. We first used siRNAs to jointly deplete both ESRP1 and ESRP2 proteins from LNCaP cells (since ESRP1 and ESRP2 can regulate overlapping targets); and in parallel treated LNCaP cells with a control siRNA. We then used RNAseq to monitor the effects of these treatments on the LNCaP transcriptome. Bioinformatic analysis ([@bib67]) of these RNAseq data (GSE129540) predicted 446 ESRP1/ESRP2 regulated alternative splicing events across 319 genes (ΔPSI \> 10%, p\<0.05) ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). We experimentally validated splicing switches for 44 predicted ESRP1/ESRP2-controlled exons by RT-PCR analysis, after LNCaP cells were treated with either of two independent sets of siRNAs directed against ESRP1 and ESRP2 or control siRNAs ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). We detected similar splicing switches for 35/44 of these skipped exons after jointly depleting ESRP1 and 2 from the AR-positive CWR22 RV1 prostate cancer cell line. 28/44 of these splicing switches were also observed after jointly depleting ESRP1 and ESRP2 from the AR positive PNT2 cells that model the normal prostate epithelium ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}).

![Identification of endogenous ESRP1/ESRP2 regulated target exons in prostate cancer.\
Heat map showing mean PSI levels for a panel of ESRP-regulated exons in prostate cancer cell lines (CWR22RV1, PNT2, LNCaP and PC3). Mean PSIs were calculated for ESRP-regulated isoforms between cells treated with siRNAs specific to ESRP1 and ESRP2, or control siRNAs (CWR22RV1, PNT2, LNCaP), between PC3 cells with and without ectopic expression of ESRP1 or ESRP2, and between LNCaP cells grown in steroid deplete versus androgen stimulated conditions (10nM R1881 for 48 hr). Biological triplicate samples were used for CWR22RV1, PNT2 and LNCaP cells, and technical replicate samples were used for RNAs prepared from PC3 cells. PSI levels were measured using RT-PCR analysis averaged from three replicates (mean data given in [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}), and clustered in the heat map according to splicing patterns across the different conditions. The heatmap was generated using heatmap.2 function using R's 'gplots' package. The black shading in the heatmap denotes non-detection of the mRNA isoform after RT-PCR, and white denotes no change detected.\
10.7554/eLife.47678.010Figure 3---source data 1.Alternative splicing events identified by Suppa2 ([@bib67]).446 ESRP regulated alternative splicing events were identified across 319 genes (ΔPSI \> 10%, p\<0.05).\
10.7554/eLife.47678.011Figure 3---source data 2.Details of 44 experimentally validated ESRP1/ESRP2 target exons identified within prostate cancer cell lines.Gene names (column A) are shown next to PSI levels detected under different experimental conditions (columns B-P). In columns B-P red cell shading indicates increased exon inclusion; blue shading indicates decreased exon splicing; the white cells labelled NA indicate these conditions were not analysed; and the white cells labelled 0 indicate no change in splicing was detected. Patterns of splicing in the PRAD dataset ([@bib63]) between tumour as compared to normal tissue (Tumour versus normal, column Q); whether there was any correlation in the PRAD dataset ([@bib63]) between splicing inclusion or exclusion of the exon with time to biochemical recurrence of the tumour (column R); the p value associated with the pattern of splicing shown in column Q (T-test p-value (BH adjusted), column S); and the difference from the median pattern of inclusion (Δ median PSI, column T) or expression in normal versus prostate tumour tissue in the PRAD cohort ([@bib63]); the coordinates of the alternative event on hg38 (Alternative event 1 (HG38), column U) and hg19 (Alternative event 1 (HG19), column V); and the forward (column W) and reverse (column X) primers used to detect the alternative event using RT-PCR.](elife-47678-fig3){#fig3}

Given this set of endogenous target exons, we carried out further analyses to next identify target exons that respond to increasing levels of either ESRP2 or ESRP1 expression in PC3 cells (which normally express low levels of endogenous ESRP1/ESRP2) ([Figure 1D and E](#fig1){ref-type="fig"}). Ectopic expression of either ESRP1 or ESRP2 in PC3 cells induced splicing switches for 31/42 exons analysed. Importantly, the splicing switches induced by ectopic expression of either ESRP2 or ESRP1 were reciprocal to the splicing switches detected after siRNA depletion of ESRP1/ESRP2 ([Figure 3](#fig3){ref-type="fig"}). Experimentally validated ESRP-regulated exons fell into two groups. Splicing of one group of exons were repressed by ectopic expression of ESRP1 or ESRP2 in PC3 cells, and reciprocally activated by endogenous ESRP1/ESRP2 depletion in LNCaP cells (these exons are in the top of the heatmap in [Figure 3](#fig3){ref-type="fig"}, from *OSBL3* to *FN1*). Splicing of the second group of exons were activated by ectopic expression of ESRP1 or ESRP2, and reciprocally repressed by ESRP1/ESRP2 depletion (from *TRIP10* to *ITGA6* in [Figure 3](#fig3){ref-type="fig"}).

An androgen steroid hormone-ESRP2 axis controls alternative splicing in AR-positive prostate cancer cells {#s2-4}
---------------------------------------------------------------------------------------------------------

The above data identified a robust panel of alternative exons within prostate cancer cells that responded to ESRP1/ESRP2 expression levels. We next tested if this panel of ESRP2-regulated exons are additionally regulated by ambient androgen concentrations. LNCaP cells were harvested after growth in steroid deplete media and after 48 hr of androgen stimulation (this timing was designed to enable full levels of androgen-mediated ESRP2 protein induction, [Figure 1H](#fig1){ref-type="fig"}). Our prediction was that androgen stimulation of LNCaP cells would activate ESRP2 expression to regulate our panel of endogenous test exons. If this was the case, splicing switches in response to androgen stimulation should occur in a reciprocal direction to splicing changes induced by ESRP1/ESRP2 protein depletion in LNCaP cells. Consistent with these expectations, more than 70% (37/44) exons in our test panel demonstrated androgen regulated splicing ([Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Importantly, plotting the percent spliced-in (PSI) for each exon after 48 hr androgen stimulation (Y axis) versus the PSI after ESRP1/ESRP2 depletion (X axis) showed a significant negative correlation (slope = −0.66, R^2^ = 0.64, p\<0.0001) ([Figure 4A](#fig4){ref-type="fig"}). Thus, exons that showed more exon skipping in response to ESRP1/ESRP2 depletion had higher splicing inclusion after androgen stimulation (which would induce ESRP2 expression) (examples shown in [Figure 4A and B](#fig4){ref-type="fig"}). Reciprocally, exons that showed higher splicing inclusion in response to ESRP1/2 depletion also had less splicing inclusion after androgen stimulation (examples shown in [Figure 4A and C](#fig4){ref-type="fig"}). These results experimentally support an androgen-ESRP2 axis that controls splicing patterns in prostate cancer cells.

![An androgen steroid hormone-ESRP2 axis controls alternative splicing in prostate cancer cells.\
(**A**) ESRP2-regulated exons are frequently also controlled by androgens in prostate cancer cells. 31/48 of the ESRP target exons (identified by RNAseq analysis of LNCaP cells depleted of ESRP1 and ESRP2) were regulated in the opposite direction in LNCaP cells treated by androgens (10nM R1881) for 48 hr (which would induce ESRP2 protein expression). Plotting the splicing responses to androgen stimulation with those after ESRP1/ESRP2 depletion revealed a negative correlation (slope = −0.66+/−0.09, Rsquare = 0.64, p\<0.0001, calculated using Graphpad). Individual values for this graph are given in [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}, and are averages from three biological replicates. (**B**) Capillary gel electrophoretograms showing splicing patterns of 3 biological replicates grown in steroid deplete media, or steroid deplete media supplemented with R1881, for alternative exons that are activated by androgen exposure in the *MINK1*, *MAP3K1*, *GRHL1*, *FLNB*, *ITGA6* and *NUMB* genes. (**C**) Capillary gel electrophoretograms showing splicing patterns of 3 biological replicates grown in steroid deplete media, or steroid deplete media supplemented with R1881, for alternative exons that are repressed by 48 hr androgen exposure in the *DOCK7*, *RPS24*, *CTNND1*, *FN1*, *MYH10* and *MAGI1* genes that were repressed by four androgen treatment. For parts (**B--C**) the p values were calculated using unpaired t tests, apart for *CTNND1* where zero inclusion of exons 2 and 3 were detected in the presence of androgens. For *CTNND1*, an RT-PCR product derived from a splice variant joining exons 1--4 via an alternative splice site is asterisked.](elife-47678-fig4){#fig4}

The genes containing ESRP-activated exons that were also activated by androgen exposure ([Figure 4B](#fig4){ref-type="fig"}) included: *MINK1* (exon 18) which encodes a pro-migratory serine/threonine kinase; *MAP3K7* (exon 12) which encodes a serine/threonine kinase that regulates signalling and apoptosis, activates NFKappaB, and is lost in aggressive prostate cancer ([@bib34]; [@bib61]); *GRLH1* (exon 5) that encodes a transcription factor involved in epithelial cell functions ([@bib31]); and *FLNB* (exon 30), alternative splicing of which has been identified as a key switch contributing to breast cancer metastasis ([@bib37]; [@bib60]). Amongst the genes containing ESRP2-repressed exons that were also skipped in response to androgen stimulation ([Figure 4C](#fig4){ref-type="fig"}) were *DOCK7* (exon 23), which encodes a guanine nucleotide exchange factor involved in cell migration ([@bib20]); and *RPS24* (exon 5), a gene that is highly expressed in prostate cancer ([@bib4]).

The AR-ESRP2 axis controls splicing of mRNA isoforms that are important for prostate cancer disease progression {#s2-5}
---------------------------------------------------------------------------------------------------------------

To visualise the amplitude of ESRP2-mediated splicing control, we plotted PSIs measured in vitro after ectopic expression of ESRP1/ESRP2 versus PSI values after siRNA mediated depletion of ESRP1/ESRP2 ([Figure 5A](#fig5){ref-type="fig"}, using data from [Figure 3](#fig3){ref-type="fig"} and [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}, slope = −0.74, R^2^ = 0.6221, p\<0.0001). Consistent with the heat map ([Figure 3](#fig3){ref-type="fig"}), ESRP2-regulated exons fell into two groups. Splicing of one group of exons were ESRP2-activated, and splicing of these were conversely repressed by ESRP1/ESRP2 depletion, while the second group of ESRP2-repressed exons had the reverse properties.

To assess how important ESRP2-regulated mRNAs might be in prostate cancer we monitored associated data for time taken to first biochemical tumour recurrence available in the TCGA PRAD cohort, in which information for 38/44 ESRP-regulated exons was available. This analysis revealed 3 groups of ESRP-regulated exons with different clinical associations. The group of ESRP1/ESRP2-promoted splice isoforms that correlated with decreased time to biochemical recurrence are shown in black on [Figure 5A](#fig5){ref-type="fig"} (individual plots are shown in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}, and the functions of these genes and their associated splice isoforms in [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Skipping of *RPS24* exon five correlates with a worse prognosis, and is the splice isoform promoted by ESRP2. Splicing inclusion of *RPS24* exon five is needed to maintain the *RPS24* open reading frame ([@bib76]). Splicing inclusion of *NUMB* exon three also correlated with a worse prognosis, and is activated by ESRP2. *NUMB* exon three encodes peptide information enabling protein interactions between NUMB and MDM2, a protein that influence p53 stability ([@bib14]).

Expression of the second group of ESRP1/ESRP2-promoted mRNA isoforms correlated with an increased time to biochemical occurrence. These exons are shown in green in [Figure 5A](#fig5){ref-type="fig"}, and include exons in the *FLNB, SLK* and *ITGA6* genes (functions of these genes and exons are summarised in [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}). For example, inclusion of *ITGA6* exon 25 is activated by ESRP2, and predicted to alter signalling pathways activated by the encoded protein ([@bib25]). Splicing inclusion of the third set of exons did not correlate with time to biochemical recurrence (identified as grey dots in [Figure 5A](#fig5){ref-type="fig"}, and summarised in [Figure 5---source data 3](#fig5sdata3){ref-type="supplementary-material"}). These exons included *GRHL1* exon 5, splicing of which is needed to maintain the *GRHL1* reading frame. *GRHL1* encodes a transcription factor important for the operation of epithelial enhancer sequences ([@bib13]; [@bib31]).

![Alternative splicing patterns controlled by the androgen steroid hormone-ESRP2 splicing axis are clinically relevant for disease progression.\
(**A**) Graphical representation of levels of average PSI levels in response to ectopic ESRP2 expression in PC3 cells (Y axis) versus after ESRP1/ESRP2 depletion in LNCaP cells. Individual PSI values to make this graph are averaged from three biological replicates, and are given in [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}. Note that the PSI values for ESRP over-expression refer to ESRP2 over-expression, with the exception of *FNIP1* and *SLC37A2* that are for ESRP1 over-expression (see [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Linear regression analysis of this data was analysed using Graphpad. Individual splice forms were correlated with clinical data for time to PSA biochemical recurrence within the PRAD cohort ([@bib63]). Points on this graph corresponding to individual ESRP-regulated splice isoforms are coloured differently according to whether they correlate with an increased time to PSA biochemical recurrence (blue dots), a decreased time to biochemical recurrence (red dots) or had no significant correlation (black dots) is shown. (**B--C**) Kaplan-Meier plots showing data from TCGA PRAD cohort of percentage of tumours that are free of biochemical recurrence versus time in years, associated with expressing the alternative splice isoforms of (**B**) *RPS24* exon 5 (PSI cut off 0.44), and (**C**) *FLNB* exon 30 (PSI cut off 0.78) ([@bib63]). (**D**) Violin plots of distributions of significance of biochemical recurrence (BCR) free survival difference between better and worse prognosis groups of patients defined by PSI cut-off values in primary tumour samples, for ESRP-regulated and all other exons whose PSI variance across TCGA primary tumours was ≥0.005 (approximately the minimum for regulated events, to avoid biasing the potential functional relevance towards these). The survival difference significance for each exon is given by -log10 of the p-value of the log-rank test used to compare survival distributions and the PSI cut-off value is the one minimising that p-value, given by *psichomics* ([@bib63]).The depicted statistical significance (**p**) of the difference between the distributions summarised by the violins was calculated with a two-sided Wilcoxon signed-rank test. (**E**) Volcano plot showing alternative splicing analysis ([@bib63]) of RNAseq data performed between normal prostate tissue and prostate tumour tissue from the TCGA PRAD cohort (consisting of 497 prostate tumour samples and 52 normal tissue). The t-test p-value (Benjamini-Hochberg adjusted for multiple testing) was used as metric of statistical significance. Significantly differentially spliced events (\|Δ median PSI\| ≥ 0.1 and FDR ≤ 0.01) are highlighted in orange, others in grey. ESRP2-activated exons are labelled in red text, and ESRP2-repressed exons are labelled in blue text. (**F**) Percentage splicing inclusion (PSI), quantified by RT-PCR, of *DOCK7* exon 23 within samples of prostate tumour and adjacent normal tissue (statistical significance calculated using t test). (**G**) Percentage splicing inclusion (PSI), quantified by RT-PCR, of *RPS24* exon 2 within nine matched samples of prostate tumour and adjacent normal tissue (statistical significance calculated using t test).\
10.7554/eLife.47678.016Figure 5---source data 1.Properties of ESRP-regulated exons that correlate with a decreased time to biochemical recurrence.\
10.7554/eLife.47678.017Figure 5---source data 2.Properties of ESRP-regulated exons that correlate with an increased time to biochemical recurrence.\
10.7554/eLife.47678.018Figure 5---source data 3.Properties of ESRP-regulated exons that show no significant correlation with time to biochemical recurrence.](elife-47678-fig5){#fig5}

To provide some measurement of the enrichment for clinically-relevant events, we compared the significance of optimal biochemical reoccurrence (BCR) survival difference between ESRP-regulated and all other exons whose PSI variance across TCGA primary tumours was ≥0.005 (approximately the minimum for regulated events, to avoid biasing the potential relevance towards these). As illustrated in the violin plot in [Figure 5D](#fig5){ref-type="fig"}, there was a significant trend for a stronger prognostic value amongst the ESRP-regulated exons.

Further analysis of the PRAD cohort revealed that 19/38 ESRP-regulated exons also have different patterns of splicing inclusion between tumour and normal tissue ([Figure 5E](#fig5){ref-type="fig"} and [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). These differentially spliced exons include the AR-ESRP2-controlled alternative exons in the *DOCK7* and *RPS24* genes (both of which were excluded in prostate tumours compared to normal prostate tissue); and the alternative exons in the *MINK1* and *MAP3K7* genes (each of which had increased levels of splicing inclusion in prostate tumours compared to normal tissue). Further qRT-PCR analysis of an independent cohort confirmed more frequent skipping of *DOCK7* (exon 23) and *RPS24* (exon 5) in prostate tumour tissue compared to normal prostate ([Figure 5F and G](#fig5){ref-type="fig"}).

Some exons had more subtle changes than would be apparent from just comparing overall exon skipping and exon inclusion in prostate cancer. *NUMB* exon three and *ITGA6* exon 25 (both activated by ESRP2) are predominantly skipped in prostate tumours compared to normal tumour tissue, yet their PSI levels increase in larger, more advanced tumours to produce their respective mRNA isoforms that are associated with a decreased time to biochemical recurrence ([Figure 5---figure supplement 2A and B](#fig5s2){ref-type="fig"}). *RAC1* exon 3A (activated by ESRP2) falls into the 'grey' area when comparing inclusion in normal versus prostate cancer, but more detailed analysis show that this exon is highly included in higher Gleason grades of prostate cancer, again to produce the *RAC1* splicing isoform associated with a decreased time to biochemical recurrence ([Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}). *RPS24* exon 5 (repressed by ESRP2, and overall more skipped in tumours) is skipped more in larger more advanced tumours, making the mRNA isoform associated with a decreased time to biochemical recurrence ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}). Similarly, *MYO1B* exon 23 (skipped in response to ESRP2) is both overall more skipped in prostate tumour versus normal, and more skipped in higher Gleason grade cancers ([Figure 5---figure supplement 2E](#fig5s2){ref-type="fig"}). FLNB exon 31 (activated by ESRP2) actually shows slightly reduced splicing inclusion in larger, more aggressive tumours ([Figure 5---figure supplement 2F](#fig5s2){ref-type="fig"}).

Splicing of key exons are switched by a drug that antagonises AR activity {#s2-6}
-------------------------------------------------------------------------

The above data identified a subset of ESRP2-regulated splicing switches that associated with biochemical recurrence of prostate cancer after treatment. Since ESRP2 expression was repressed by ADT in patient prostate cancer tissue, we next investigated whether AR inactivation may influence mRNA splice isoforms that correlate with cancer progression. To test this, androgen induction of *ESRP2* mRNA expression was blocked using the androgen antagonist bicalutamide (Casodex) ([Figure 6A](#fig6){ref-type="fig"}). Consistent with Casodex preventing expression of some potentially harmful isoforms in prostate cancer cells, the splicing inclusion of *NUMB* exon three and *TUFT1* exon two were reduced by Casodex (both these exons are normally activated by androgen exposure and ESRP2). Likewise, exon skipping events in the *RPS24*, *FN1* and *MYH10* genes that correlated with a poorer prognosis were also reduced by Casodex (these exons are normally skipped in response to ESRP2). Not all the splicing switches induced by Casodex correlate with increased time to biochemical recurrence. Skipping of *CTNND1* exon 2 and 3 correlates with a decreased time to biochemical recurrence within the TGCA dataset ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), and this is the mRNA isoform promoted by Casodex treatment ([Figure 6C](#fig6){ref-type="fig"}). Splicing inclusion of *MAGI1* exon 7 (normally repressed by ESRP2) and *RALGPS2* exon 15 were also increased by Casodex treatment ([Figure 6B and C](#fig6){ref-type="fig"}).

![Pharmacological inhibition of AR function switches ESRP2-dependent splicing patterns.\
(**A**) *ESRP2* mRNA expression in cells grown in steroid deplete (SD) conditions, and after addition of androgens (A+) (quantified by real-time PCR from three biological replicates). Androgen-mediated activation of *ESRP2* expression was inhibited in the presence of 10 μM of the anti-androgen bicalutamide (Casodex). Cells were cultured for 24 hr. The p value shows the statistical significance that was calculated using a t test between the A + vehicle and the A + casodex samples. (**B--C**) Capillary gel electrophoretogram showing RT-PCR analysis the splicing response + /- 24 hr Casodex treatment for exons that are normally (**B**) activated or (**C**) repressed by androgens (three biological samples shown, statistical significances were calculated using a t test, with the exception of *CTNND1* where there was zero inclusion detected for exons 2 and 3 before depletion of ESRP2, and FN1 where there was zero inclusion of exon 25 before Casodex treatment).](elife-47678-fig6){#fig6}

ESRP2 and ESRP1 are important to maintain epithelial splicing programmes. We thus considered whether by repressing ESRP2 expression, ADT might also inadvertently switch splicing towards mesenchymal patterns that could facilitate metastasis. Consistent with this prediction, treatment of LNCaP cells with Casodex reduced splicing inclusion levels of the *FLNB* gene exon 30 by almost 20% ([Figure 6B](#fig6){ref-type="fig"}). Although it is not differentially spliced between normal prostate and prostate cancer ([Figure 5E](#fig5){ref-type="fig"}), increased skipping of *FLNB* exon 30 has been recently reported as a key driver of EMT in breast cancer development ([@bib37]). Similarly, Casodex treatment also increased splicing inclusion of what are normally mesenchymal-expressed exons in the *CTNND1* gene ([@bib78]) ([Figure 6C](#fig6){ref-type="fig"}).

We used siRNA as a further strategy to reduce AR expression ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). As predicted, ESRP2 protein expression was reduced by siRNA depletion of the AR ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Furthermore, siRNA-mediated depletion of AR reduced levels of *FLNB* splicing inclusion from 84% to 69%, and levels of *TUFT1* exon 2 splicing from 23% to 9% ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}). Both these data support a scenario where splicing inclusion of ESRP2-dependent exons are controlled by expression levels of the AR.

Splicing patterns respond to changes in the expression of ESRP2 alone {#s2-7}
---------------------------------------------------------------------

The above data suggested a model where decreases in ESRP2 expression in response to inhibition of AR activity are sufficient to induce splicing changes, even though ESRP1 was still expressed. To further investigate whether loss of ESRP2 alone would be sufficient to induce splicing changes we carried out individual siRNA-mediated depletion of ESRP2 both within both LNCaP and CWR22RV1 cells. Consistent with our model, single ESRP2 depletion was able to switch splicing patterns of exons within the *MAP3K7*, *ARFGAP2* and *CTNND1* genes ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}; [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). As examples, individual depletion of ESRP2 reduced splicing inclusion of *MAP3K7* exon 12, and activated splicing inclusion of *CTNND1* exons 2 and 3 ([Figure 6](#fig6){ref-type="fig"} -- [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Furthermore, splicing patterns of ESRP1/ESRP2 target exons were also responsive to single up-regulation of either ESRP1 or ESRP2 ([Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}).

Discussion {#s3}
==========

In this study we report a novel molecular mechanism that explains how androgen steroid hormones control splicing patterns in prostate cancer cells, and unifies the functions of the AR both as a transcription factor and being able to control splicing. In this model, the AR controls expression of the master splicing regulator protein ESRP2, which then regulates the splicing patterns of key genes important for prostate cancer biology ([Figure 7](#fig7){ref-type="fig"}). Amongst the key data supporting this proposed model, we find that *ESRP2* is a direct and early target for transcriptional activation by the AR in prostate cancer cells. Furthermore, endogenous splice isoform patterns controlled by ESRP1 and ESRP2 also respond to androgen stimulation, siRNA-mediated depletion of the AR and/or the AR inhibitor bicalutamide (Casodex). While intuitively straightforward, this model is conceptually different from the mechanisms through which estrogen and progesterone have been shown to regulate splicing (via recruitment of splicing regulators as transcriptional cofactors, and by modulation of transcription speeds and chromatin structure).

![Model describing how exposure to androgens regulates splicing patterns in prostate cancer cells.\
Androgen exposure leads to transcription of the gene encoding the master splicing regulator protein *ESRP2*. This promotes epithelial splicing patterns within prostate cancer cells. Lower levels of circulating androgens after ADT lead to transcriptional repression of *ESRP2*. This results in a dampening of epithelial splicing patterns, and production of normally mesenchymal splice patterns including for the *FLNB*, *CTNND1* and *MAP3K7* genes. This image was created using BioRender.](elife-47678-fig7){#fig7}

Androgens are already known to substantially modify transcriptional levels in prostate cancer, with important implications for cell behaviour and cancer progression ([@bib49]). The data presented here imply that androgens also have an important role in controlling splicing patterns, particularly those that relate to epithelial/mesenchymal functions. Previous studies identified just a small number of alternative exons that are controlled by androgens in prostate cancer cells, none of which overlapped with the current study ([@bib50]; [@bib58]). We suggest that an important reason for this discrepancy is because previously splicing patterns were monitored after 24 hr of androgen exposure. Since we now show that splicing regulation by androgens operates indirectly through transcriptional control of ESRP2, 24 hr androgen exposure would not be sufficient to upregulate ESRP2 levels. In the current study we analysed androgen-dependent splicing switches after 48 hr, to allow sufficient time for ESRP2 induction at the protein level and re-equilibration of downstream splice isoform ratios. ESRP1 expression levels also decreased in prostate tumours following ADT so might also be under androgen-control in tissue, although did not reciprocally increase following androgen stimulation of cultured cells.

ESRP1 has recently been shown to be amplified in an aggressive subgroup of early onset prostate cancer, but how this contributes to disease progression has been not well understood ([@bib21]). Our data here show that ESRP1 and ESRP2 control a number of individual mRNA splice isoforms that correlate with time to biochemical recurrence ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), including of *MAP3K7* exon 12 inclusion which is associated with a shorter time to biochemical reoccurrence in the TGCA database. Deletion of the *MAP3K7* gene occurs in 30--40% of prostate tumours, and is associated with a poor clinical prognosis ([@bib22]; [@bib34]; [@bib39]; [@bib80]). *MAP3K7* is a key gene in prostate cancer, and *MAP3K7* exon 12 splicing is associated with epithelial properties of prostate cancer cells ([@bib16]). More generally, epithelial splicing patterns may play an important role early in prostate cancer development in establishing primary tumours ([Figure 7](#fig7){ref-type="fig"}).

The expression of ESRPs appears to be plastic during cancer progression ([@bib26]; [@bib30]; [@bib69]). ESRPs have previously been shown to have a dual role in carcinogenesis with both gain and loss associated with poor patient prognosis ([@bib26]). ESRP1 expression is linked to poor survival and metastasis in lung cancer ([@bib82]), and both ESRP1 and ESRP2 are upregulated in oral squamous cell carcinoma relative to normal epithelium ([@bib30]). Since ESRP2 is a critical component of epithelial-specific splicing programmes, we suggest that down-regulation of ESRP2 levels in response to ADT could dampen epithelial splicing patterns, helping to prime prostate cancer cells for future mesenchymal development and possibly contribute to development of metastasis. Supporting this, mesenchymal splicing patterns were induced by bicalutamide (Casodex) treatment of LNCaP cells, including in the *FLNB*, *CTNND1* and *MAP3K7* genes. *FLNB* encodes an actin binding protein which is linked to cancer cell motility and invasion ([@bib15]; [@bib29]). Skipping of *FLNB* exon 30 is sufficient to initiate metastatic progression in breast cancer ([@bib37]). In experiments reported here androgens promote the FLNB isoform that is not associated with metastasis. Expression of the metastatic *FLNB* variant is promoted by bicalutamide (Casodex) treatment. In breast cancer, the metastatic effects of FLNB alternative splicing are mediated via the FOXC1 transcription factor. The role FOXC1 plays in prostate cancer progression is unknown, but FOXC1 expression may be linked to androgen receptor levels ([@bib71]). ESRP2 also promotes skipping of epithelial-expressed exons in the *CTNND1* gene (catenin delta 2, encoding a protein involved in cell adhesion and signalling), while Casodex treatment induces expression of a normally mesenchyme-specific splice isoform ([@bib78]). The Map3k12Δexon12 splice isoform is produced in response to ESRP2 depletion, and is usually expressed in highly metastatic cancer cell lines ([@bib68]).

The clinical prognosis of metastatic prostate cancer is poor ([@bib40]). This makes the mechanisms that control metastasis of prostate cancer cells, and any links with ADT of prime importance. In prostate cancer EMT has been linked to a common mechanism underlying therapeutic resistance and is associated with poor prognosis ([@bib24]). Sun et al. showed that although ADT can effectively control prostate tumour size initially, it simultaneously promotes EMT, an unintended consequence that could ultimately lead to CRPCa ([@bib64]). Such direct links between ADT and EMT uncover an important yet overlooked consequence of the standard care treatment for advanced prostate cancer ([@bib9]). Although the causes of EMT in prostate cancer progression to CRPCa are likely to be complex, the down-regulation of ESRP proteins has been shown to be essential for EMT progression ([@bib27]). Thus, loss of ESRP expression may provide a molecular explanation why AR positive prostate cancer cells show increased susceptibility to EMT in response to ADT, and so is relevant to consider with regard to therapy. Our findings have important implications for second line treatment strategies in a clinical setting, and suggest an alternative approach may be to inhibit EMT in combination with ADT to prevent disease progression.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\              Designation                                            Source or reference                                                                           Identifiers             Additional\
  (species) or\                                                                                                                                                                                           information
  resource                                                                                                                                                                                                
  -------------------------- ------------------------------------------------------ --------------------------------------------------------------------------------------------- ----------------------- ------------------------------------------------
  Gene (*H. sapiens*)        *ESRP1*                                                                                                                                                                      

  Gene (*H. sapiens*)        *ESRP2*                                                                                                                                                                      

  Cell line (*H. sapiens*)   LNCaP                                                  ATCC                                                                                          CRL-1740                

  Cell line (*H. sapiens*)   PC3                                                    ATCC                                                                                          CRL-1435                

  Cell line (*H. sapiens*)   CWR-RV1                                                ATCC                                                                                          CRL-2505                

  Cell line (*H. sapiens*)   PNT2                                                   Sigma Aldrich                                                                                 95012613                

  Cell line (*H. sapiens*)   RWPE-1                                                 ATCC                                                                                          CRL-11609               

  Antibody                   Rabbit polyclonal anti-ESRP2                           Genetex                                                                                       GTX123665               1:1000 dilution

  Antibody                   Rabbit polyclonal anti-ESRP1                           Sigma,                                                                                        HPA023719               1:1000 dilution

  Antibody                   Mouse monoclonal anti-AR                               BD Bioscience,                                                                                554226                  1:10000 dilution

  Antibody                   anti-actin rabbit polyclonal antibody                  Sigma                                                                                         A2668                   1:2000 dilution

  Antibody                   anti-FLAG mouse monoclonal antibody                    Sigma                                                                                         F3165                   1:2000 dilution

  Antibody                   normal rabbit IgG                                      Jackson labs                                                                                  711-035-152             1:2000 dilution

  Antibody                   normal mouse IgG                                       Jackson labs                                                                                  715-036-150             1:2000 dilution

  Recombinant DNA reagent    ESRP1 plasmid                                          Gift from Prof Russ Carstens (University of Philadelphia. USA)                                PIBX-C-FF-B-ESRP1       

  Recombinant DNA reagent    ESRP2 plasmid                                          Gift from Dr Keith Brown (University of Bristol. UK)                                          pBIGi hESRP2-FLAG       

  Sequence based reagent     Primers to detect splice isoforms                      This paper                                                                                                            designed using Primer3 <http://primer3.ut.ee/>

  Sequence based reagent     qPCR primers                                           This paper                                                                                                            designed using Primer3 <http://primer3.ut.ee/>

  Sequence based reagent     siRNAs                                                 hs.Ri.ESRP1.13.1, hs.Ri.ESRP1.13.2, hs.Ri.ESRP2.13.1, hs.Ri.ESRP2.13.2, IDT (51-01-14-04),\                           
                                                                                    AR esiRNA EHU025951\                                                                                                  
                                                                                    Control esiRNA EHUEGFP Sigma                                                                                          

  Commercialassay or kit     Rnaeasy plus kit                                       Qiagen                                                                                        catalog number 74134    

  Commercialassay or kit     DNA free                                               Ambion                                                                                        catalog number AM1906   

  Software, algorithm        Graphpad prism                                         <https://graphpad.com>                                                                                                

  Chemical compound, drug    synthetic androgen analogue methyltrienolone (R1881)   Perkin--Elmer                                                                                 NLP005005MG             10 nM

  Chemical compound, drug    Bicalutamide (Casodex)                                 Sigma                                                                                         B9061                   10 μM
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines and cell culture {#s4-1}
---------------------------

Cell culture and androgen treatment of cells was as described previously ([@bib46]; [@bib47]; [@bib48]; [@bib45]; [@bib58]). All cells were grown at 37°C in 5% CO2. LNCaP cells (CRL-1740, ATCC) were maintained in RPMI-1640 with L-Glutamine (PAA Laboratories, R15-802) supplemented with 10% Fetal Bovine Serum (FBS) (PAA Laboratories, A15-101). For androgen treatment of LNCaP cells, medium was supplemented with 10% dextran charcoal stripped FBS (PAA Laboratories, A15-119) to produce a steroid-deplete medium. Following culture for 72 hr, 10 nM synthetic androgen analogue methyltrienolone (R1881) (Perkin--Elmer, NLP005005MG) was added (Androgen +) or absent (Steroid deplete) for the times indicated. Similarly, LNCaP cells were pre-treated with with 10 μM bicalutamide (Casodex) or ethanol (vehicle) for 2 hr prior to addition of 10nM R1881 for 48 hr. Cell line validation was carried out using STR profiling was according to the ATCC guidelines. All cell lines underwent regular mycoplasma testing.

Antibodies {#s4-2}
----------

The following antibodies were used for western blotting: Anti-ESRP2 rabbit antibody (Genetex, GTX123665), anti-rabbit ESRP1 (Sigma, HPA023719), anti-AR mouse antibody (BD Bioscience, 554226), anti-actin rabbit antibody (Sigma, A2668), anti-FLAG mouse monoclonal antibody (Sigma, F3165), normal rabbit IgG (711-035-152 Jackson labs) and normal mouse IgG (715-036-150 Jackson labs). For immunohistochemistry the following ESRP antibodies were tested: anti-rabbit ESRP1 (Sigma, HPA023719) and anti-rabbit ESRP2 (Abcam ab113486) but were found not to be specific for FFPE cell pellets.

RT-qPCR {#s4-3}
-------

Cells were harvested and total RNA extracted using TRI-reagent (Invitrogen, 15596--026), according to the manufacturer's instructions. RNA was treated with DNase 1 (Ambion) and cDNA was generated by reverse transcription of 500 ng of total RNA using the Superscript VILO cDNA synthesis kit (Invitrogen, 11754--050). Quantitative PCR (qPCR) was performed in triplicate on cDNA using SYBR Green PCR Master Mix (Invitrogen, 4309155) using the QuantStudio 7 Flex Real-Time PCR System (Life Technologies). ESRP1 was detected using (ESRP1 for AGCACTACAGAGGCACAAACA; ESRP1 Rev TGGAGAGAAACTGGGCTACC). ESRP2 was detected using the primer combination (ESRP2 For CCT GAA CTA CAC AGC CTA CTA CCC; ESRP2 Rev TCC TGA CTG GGA CAA CAC TG). Samples were normalised using the average of three reference genes: GAPDH (GAPDH For AAC AGC GAC ACC CAT CCT C; GAPDH Rev TAGCACAGCCTGGATAGCAAC); β--tubulin (TUBB For CTTCGGCCAGATCTTCAGAC; TUBB Rev AGAGAGTGGGTCAGCTGGAA); and actin (ACTIN For CATCGAGCACGGCATCGTCA; ACTIN Rev TAGCACAGCCTGGATAGCAAC).

siRNA {#s4-4}
-----

siRNA mediated protein depletion of ESRP1/2 was carried out using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher, 13778075) as per the manufacturer's instructions and for the times indicated. The siRNA sequences used were ESRP1 siRNA1 (hs.Ri.ESRP1.13.1); ESRP1 siRNA2 (hs.Ri.ESRP1.13.2); ESRP2 siRNA 1 (hs.Ri.ESRP2.13.1); ESRP2 siRNA 2 (hs.Ri.ESRP2.13.2); and a negative control siRNA (IDT (51-01-14-04)). AR esiRNA was as described previously ([@bib49]).

Immunohistochemistry {#s4-5}
--------------------

Freshly cut tissue sections were analysed for immunoexpression using Ventana Discovery Ultra autostainer (Ventana Medical Systems, Tucson, Arizona). In brief, tissue sections were incubated in Cell conditioning solution 1 (CC1, Ventana) at 95°C to retrieve antigenicity, followed by incubation with respective primary antibodies described above. Bound primary antibodies were visualized using UltraMap DAB anti-Rb Detection Kit.

AR-ChIP {#s4-6}
-------

LNCaP cells were stimulated with 10 nM R1881 overnight. The ChIP assay was performed using the one step ChIP kit (Abcam ab117138) as per manufacturer's instruction. Briefly, cells were fixed and crosslinked in 1% formaldehyde for 10 min at 37°C and incubated with protease inhibitors. Chromatin was isolated from cell lysates and enzymatically fragmented using an EZ-Zyme Chromatin Prep Kit (Merck 17 375). 10 ug of anti - AR antibody (Abcam ab74272) or IgG control antibody was used to precipitate DNA crosslinked with the androgen receptor. Enriched DNA was then probed by qPCR using primers targeting the ESRP2 regulatory region to assess AR binding intensity. Primer sequences used to detect PSA were (PSA ChIP for GCC TGG ATC TGA GAG AGA TAT CAT C; PSA Chip rev ACA CCT TTT TTT TTC TGG ATT GTT G). Primers used to detect AR binding near to ESRP2 were (ESRP2 Chip for TCCCGAGTAGCTGGGACTAC; ESRP2 Chip rev CAGTGGCTTACACCTGGGAG).

Creation of PC3 stable cell lines {#s4-7}
---------------------------------

The ESRP1 plasmid (PIBX-C-FF-B-ESRP1) was a gift from Prof Russ Carstens (University of Philadelphia. USA) and the ESRP2 plasmid (pBIGi hESRP2-FLAG) from Dr Keith Brown (University of Bristol, UK). PC3 cells were transfected using FuGene HD Transfection Reagent as per manufacturer's instructions. Stable transfectants with ESRP1 was selected using 10 µg/ml Blasticidin and ESRP2 plasmid was selected using 150 ug/ml Hygromycin. ESRP2 Plasmid was inducible by 2.5 ug/ml doxycycline for 48 hr. PC3 ESRP1 overexpressed cells were transfected with pBIGi hESRP2-FLAG plasmid using the same protocol.

In vitro cell proliferation analysis {#s4-8}
------------------------------------

For cell growth curves (carried out for in vitro analysis of PC3 stable cell lines), PC3 cells were seeded 100,000 cells per well in 12-well plate in eight plates. Cells were counted every 24 hr after seeding in the plate. All the treatments had 12 repeats. WST assays were carried out over 7 days as per manufacturer's instructions (Cayman, CAY10008883). For DU145 cells 10,000 cells were seeded per well in a 96 well plate. All data was tested by two-way ANOVA.

RNAseq analysis {#s4-9}
---------------

LNCaP cells (passage 19) were treated with either control siRNAs or siRNAs targeting ESRP1 and ESRP2 for 72 hr (samples prepared in triplicate). RNA was extracted 72 hr after siRNA treatment using the Qiagen RNAeasy kit (Cat No. 74104) as per the manufacturer\'s instructions. RNAseq was carried out using TruSeq Stranded mRNA Sequencing NextSeq High-Output to obtain 2 × 75 bp reads. Quality control of reads was performed using FastQC. Reads were mapped to the hg38 transcriptome using Salmon. Differential gene expression analysis was performed using DESeq2. Percent spliced-in (PSI) estimates for splicing events were calculated using SUPPA2 ([@bib67]) based on isoform transcripts per million (TPM) estimates from Salmon ([@bib54]). Quantification utilised Gencode gene models (release 28). Differential PSI was calculated using DiffSplice using the empirical method ([@bib28]). Events with a delta PSI \> 10% and FDR \< 0.05 were considered as significant.

*Psichomics* and bioinformatic analysis of PRAD cohort {#s4-10}
------------------------------------------------------

Clinical expression patterns of ESRP2-regulated exons were monitored using *psichomics* ([@bib63]). Differential splicing analysis between primary solid tumour and solid tissue normal samples were subsequently performed to evaluate relative higher inclusion levels in either tumour or normal tissue samples using Δ median and t-test p-value (Benjamini-Hochberg adjusted) values. Survival analysis based on TCGA clinical data derived from prostate cancer patient samples was performed with time to first PSA biochemical recurrence being the event of interest. Additional statistical analyses and generation of plots were performed in *R* ([@bib56]). Violin plots were created with R package *vioplot* ([@bib1]).

Tumour xenografts {#s4-11}
-----------------

Stable overexpression of *ESRP1* and stable doxycycline-inducible overexpression of either *ESRP2* alone or *ESRP1* and *2* were obtained using PC3 cells (that have the low endogenous levels of both proteins). One million PC3 overexpressing *ESRP1* or control cells were injected subcutaneously in the flank of male nude mice and tumour volumes were monitored. Two million PC3 cells overexpressing *ESRP2*, overexpressing *ESRP1* and *2*, or control cells were injected subcutaneously in the flank of male nude mice and tumour volumes were monitored. PC3 ESRP2 and PC3 ESRP1/2 cells were cultured in medium supplemented with 2.5 ug/ml doxycycline for 48 hr prior to injecting into nude mice to induce ESRP2 expression and mice were administered Doxycycline repeatedly. Tumour diameters were measured using calipers.

Clinical samples {#s4-12}
----------------

Our study made use of RNA from 32 benign samples from patients with benign prostatic hyperplasia (BPH) and 17 malignant samples from transurethral resection of the prostate (TURP) samples. Malignant status and Gleason score were obtained for these patients by histological analysis. We also analysed normal and matched PCa tissue from nine patients obtained by radical prostectomy. The samples were obtained with ethical approval through the Exeter NIHR Clinical Research Facility tissue bank (Ref: STB20). Written informed consent for the use of surgically obtained tissue was provided by all patients. The RNA samples analysed in [Figure 2C](#fig2){ref-type="fig"} were previously published ([@bib74]).

Statistical analyses {#s4-13}
--------------------

All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc). Statistical analyses were conducted using the GraphPad Prism software (version 5.04/d). PCR quantification of mRNA isoforms was assessed using the unpaired student's t-test. Data are presented as the mean of three independent samples ± standard error of the mean (SEM). Statistical significance is denoted as \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 and \*\*\*\*p\<0.0001.
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Summary:

The manuscript from Munkley, Elliott and colleagues shows that the epithelial splicing regulator *ESRP2* is transcriptionally upregulated by the androgen receptor (AR), an observation based on a previous study of gene expression changes in response to androgen in the androgen receptor positive LNCaP prostate cancer cell line by some of these investigators. *ESRP2* upregulation leads to a series of changes in alternative splicing, including switches with potential effects in disease relapse and metastasis which correlate with disease outcomes. Prostate cancer is driven by androgens via AR, and therapy involves androgen deprivation (ADT) to slow progression. However, it has also been reported that ADT promotes epithelial mesenchymal transition (EMT) (e.g. Sun et al., 2012), which might be related to the common progression to castration resistant prostate cancer following ADT. Munkley et al. show that levels of ESRP2 are reduced after androgen deprivation in 7 prostate cancer patients. A number of other analyses using additional cell lines, a xenograft model, and data from other published prostate cancer samples leads to a general proposal that a decrease in *ESRP2* expression (but not *ESRP1*) and some splicing changes associated with its depletion following androgen deprivation may be associated with prostate cancer progression and worse outcomes. One highlighted example is exon 30 in *FLNB*, skipping of which is associated with metastatic progression in breast cancer.

A number of papers describing roles for *ESRP1/2* in various cancers including breast, colorectal, lung, and ovarian carcinomas have yielded conflicting conclusions on the role of ESRPs or epithelial-specific isoforms it regulates, such as CD44, in cancer progression and/or patient outcomes. In some cases ESRPs are proposed to be tumor suppressors, whereas in other cases they are proposed to promote more aggressive cancers (see, for example, Zhang et al., Genes and Dev 33: 166-179 and references therein). As cited by the authors, a recent manuscript reports that duplication and increased expression of *ESRP1* (which would largely promote the same splicing events as *ESRP2*) is associated with more aggressive human prostate cancers. Thus, a central question is whether the current manuscript can provide further clarity regarding the general role of ESRPs (including ESRP2) in cancer, including prostate cancer.

Munkley et al. raise the clinically-relevant point that current treatments for prostate cancer might have undesirable side-effects by inhibiting *ESRP2* mediated splicing events. Overall, the manuscript is clearly presented. The data documenting the ESRP and AR regulated splicing program, and the restriction of tumor growth by ESRPs (Figures 1-4, 6) are very clear with very nice correlations between responses to ESRP overexpression, knockdown and androgen stimulation.

Essential revisions:

1\) A key concern relates to the relative levels and effects of ESRP1 and ESPR2 under conditions of androgen induction or ADT in prostate cells. The authors do a good job documenting that *ESRP2* is under transcriptional control of the androgen receptor, while *ESRP1* is not, and that there is a 2-fold reduction in *ESPR2* expression post-ADT in cancer samples. On the other hand, (a) both *ESRP1* and *ESRP2* seem down-regulated at the protein level in androgen receptor-negative prostate cancer cells lines (probably by different mechanisms), (b) both *ESRP1* and *ESRP2* mRNAs are up-regulated in tumor samples compared to controls, (c) both *ESRP1* and *ESRP2* are up-regulated in a cohort of metastatic patient samples, (d) the correlation between ESRP levels and recurrence free survival is a more significant for *ESRP1* than *ESRP2*, and (e) a number of functional assays from this manuscript and other publications argue that both *ESRP1* and *ESPR2* can contribute to regulate overlapping targets relevant for epithelial-specific splicing. Therefore one key question that remains is to what extent the androgen-mediated transcriptional regulation of *ESRP2* does contribute to splicing regulation in the context of the relative levels/activities of *ESRP1*: while a number of the results presented show that androgen treatment can promote splicing towards a stronger \"epithelial\" pattern, the authors should make additional efforts to demonstrate that ablation of *ESRP2* alone (in the presence of *ESRP1*) leads to substantial changes in splicing that would be expected to explain the association of a loss of *ESRP2* with worse outcomes, which is an essential point for the validity of their model. For example, an analysis similar to that of Figure 1A for *ESRP1* should be included, as well as other experiments aimed to determine whether the activity of *ESRP1* can buffer the effects of ATD on *ESRP2*.

2\) There is also a need for clarity in terms of the coherence of the predicted biological effects of the alternative splice site switches and at least one proof-of-principle demonstration that they are relevant for any property of prostate cells relevant to cancer, as it is difficult to draw firm conclusions from the data presented as to whether the regulation of *ESRP2* by androgens is definitively associated with prostate cancer progression or outcomes in a positive or negative manner.

a\) Figure 5A shows exons that are more included or skipped in prostate cancer vs. normal using TCGA data. But only 6 of the 44 ESRP-AR regulated events are highlighted on the plot, two of which do not change significantly, including FLNB which is highlighted in the Abstract and is the only event used to test the response to the AR antagonist Casodex. All of the events from Figure 3 should be highlighted in Figure 5A, with ESRP activated and repressed exons clearly distinguished by colour or symbol. The authors should explain -- when known -- the nature of the differential activities of the isoforms and whether the isoform switch observed in the presence of androgens/mediated by ESRPs is predicted to contribute, repress or be neutral to tumor cell growth, apoptosis, motility, metastasis, etc. and therefore whether a functionally coherent program of alternative splicing is coordinated by ERSPs or whether various contrasting contributions are predicted whose relative significance will depend on context, etc. If not, is it possible to stratify the data e.g. by tumor grade, or by ESRP expression level? Would this for instance, reveal different classes where events such as FLNB do show a difference between cancer and normal in some classes?

b\) In Figure 6, why is *FLNB* e30 the only splicing event monitored for response to Casodex -- especially since this is one of the events that is not altered between prostate cancer and normal tissue? This figure should be more systematic with more splicing events.

c\) Increased inclusion of exon 30 in *FLNB* (which occurs for example upon androgen stimulation) is consistent with inhibition of EMT (something that could be stated more clearly in the text). But there is no mechanistic model presented as to how a change in *FLNB* splicing (or other targets) impacts prostate CA. What about the other alternative splicing events highlighted in Figures 4/5? Even if *FLNB* splicing switches have been shown to influence expression of EMT markers in breast cancer cells (Li et al., 2018), it will be essential to show that the degree of switch observed in prostate cancer cells (for *FLNB* or any other gene) has a relevant biological readout.

10.7554/eLife.47678.028

Author response

> Essential revisions:
>
> 1\) A key concern relates to the relative levels and effects of ESRP1 and ESPR2 under conditions of androgen induction or ADT in prostate cells. The authors do a good job documenting that ESRP2 is under transcriptional control of the androgen receptor, while ESRP1 is not, and that there is a 2-fold reduction in ESPR2 expression post-ADT in cancer samples. On the other hand, (a) both ESRP1 and ESRP2 seem down-regulated at the protein level in androgen receptor-negative prostate cancer cells lines (probably by different mechanisms), (b) both ESRP1 and ESRP2 mRNAs are up-regulated in tumor samples compared to controls, (c) both ESRP1 and ESRP2 are up- regulated in a cohort of metastatic patient samples, (d) the correlation between ESRP levels and recurrence free survival is a more significant for ESRP1 than ESRP2, and (e) a number of functional assays from this manuscript and other publications argue that both ESRP1 and ESPR2 can contribute to regulate overlapping targets relevant for epithelial-specific splicing. Therefore one key question that remains is to what extent the androgen-mediated transcriptional regulation of ESRP2 does contribute to splicing regulation in the context of the relative levels/activities of ESRP1: while a number of the results presented show that androgen treatment can promote splicing towards a stronger \"epithelial\" pattern, the authors should make additional efforts to demonstrate that ablation of ESRP2 alone (in the presence of ESRP1) leads to substantial changes in splicing that would be expected to explain the association of a loss of ESRP2 with worse outcomes, which is an essential point for the validity of their model. For example, an analysis similar to that of Figure 1A for ESRP1 should be included, as well as other experiments aimed to determine whether the activity of ESRP1 can buffer the effects of ATD on ESRP2.

This is a good point. We had not previously considered androgen regulation of *ESRP1*, since only *ESRP2* originally was identified as a reciprocally regulated gene after acute androgen stimulation versus ADT. We now show that *ESRP1* mRNA levels do decrease in response to ADT (new Figure 1A), and confirm that only *ESRP2* mRNA levels increase in response to androgen stimulation of tissue culture cells. We also have carried out single siRNA depletion of *ESRP2*. This is sufficient to change splice isoform ratios (even in the presence of ESRP1) for 3 candidate events that we have tested (new Figure 6 ---figure supplement 2). We also present data in Figure 3, where we have over-expressed either ESRP1 or ESRP2 alone in PC3 cells (which have low endogenous ESRP expression levels), and show that either can induce splicing responses.

> 2\) There is also a need for clarity in terms of the coherence of the predicted biological effects of the alternative splice site switches and at least one proof-of-principle demonstration that they are relevant for any property of prostate cells relevant to cancer, as it is difficult to draw firm conclusions from the data presented as to whether the regulation of ESRP2 by androgens is definitively associated with prostate cancer progression or outcomes in a positive or negative manner.
>
> a\) Figure 5A shows exons that are more included or skipped in prostate cancer vs. normal using TCGA data. But only 6 of the 44 ESRP-AR regulated events are highlighted on the plot, two of which do not change significantly, including FLNB which is highlighted in the Abstract and is the only event used to test the response to the AR antagonist Casodex. All of the events from Figure 3 should be highlighted in Figure 5A, with ESRP activated and repressed exons clearly distinguished by colour or symbol.

We now add all this information in the format requested (this updated volcano plot is now Figure 5E).

> The authors should explain -- when known -- the nature of the differential activities of the isoforms and whether the isoform switch observed in the presence of androgens/mediated by ESRPs is predicted to contribute, repress or be neutral to tumor cell growth, apoptosis, motility, metastasis, etc. and therefore whether a functionally coherent program of alternative splicing is coordinated by ERSPs or whether various contrasting contributions are predicted whose relative significance will depend on context, etc.

We now add three supplementary tables that describe the known functions of ESRP2-regulated exons. These are the new Figure 5---source data 1 (ESRP2-regulated splices that correlate with a shorter time to biochemical recurrence); the new Figure 5---source data 2 (ESRP2-regulated splices that correlate with an increased time to biochemical recurrence); and the new Figure 5---source data 3(ESRP2-regulated splices that do not significantly correlate with time to biochemical recurrence). We discuss the possible functions of these exons on prostate tumours in the text and figure supplements (e.g. *RAC1* exon 3b is known from the literature to promote tumour cell migration).

> If not, is it possible to stratify the data e.g. by tumor grade, or by ESRP expression level? Would this for instance, reveal different classes where events such as FLNB do show a difference between cancer and normal in some classes?

We include data now where we have stratified data by tumour grade (this is the new Figure 5---figure supplement 2). This shows that some exons (e.g. *FLNB, NUMB, ITGA6, RAC1* do show differences when tumour grades are considered)

> b\) In Figure 6, why is FLNB e30 the only splicing event monitored for response to Casodex -- especially since this is one of the events that is not altered between prostate cancer and normal tissue? This figure should be more systematic with more splicing events.

We now make an updated Figure 6more systematic, containing electrophoretograms for more splicing events. We also include more extensive casodex data within an updated Figure 3---source data 2. Since the updated Figure 6 is now more extensive, we have moved the AR siRNA splicing figure to a new Figure 6---figure supplement 1. This AR siRNA splicing figure also contains many more examples that those we initially showed in our original manuscript.

> c\) Increased inclusion of exon 30 in FLNB (which occurs for example upon androgen stimulation) is consistent with inhibition of EMT (something that could be stated more clearly in the text). But there is no mechanistic model presented as to how a change in FLNB splicing (or other targets) impacts prostate CA. What about the other alternative splicing events highlighted in Figures 4/5? Even if FLNB splicing switches have been shown to influence expression of EMT markers in breast cancer cells (Li et al., 2018), it will be essential to show that the degree of switch observed in prostate cancer cells (for FLNB or any other gene) has a relevant biological readout.

We now discuss more clearly that increased inclusion of *FLNB* e30 is consistent with inhibition of EMT, and how in response to Casodex prostate cancer cells express mesenchymal isoforms of *FLNB, CTNND1* and *MAP3K7*. To address the function of these splicing switches we include three new supplementary tablesthat discuss the known biological readouts of androgen/ESRP-regulated exons (new Figure 5---source data 1-3). To address the potential impact of these splicing events in prostate cancer, we include Kaplan-Meier plots that correlate splicing switches with time to tumour biochemical recurrence (updated Figure 5 ---figure supplement 1). We also only include now exons in these plots for which there are sufficient patients to draw firm conclusions about isoform levels relative to biochemical recurrence).

[^1]: These authors contributed equally to this work.
